Abstract:Importance Depression is associated with alterations in blood immuno-metabolic biomarkers, but it remains unclear whether these alterations are limited to select measures or represent broader patterns and can predict depression diagnosis. Objective To examine immuno-metabolic biomarker changes in depression, pattern of effect at the symptom and symptom-dimension level, and prediction of depression diagnosis. Design, Setting, and Participants Case-control and cohort-wide analyses of ICD-10 depression, depressive and anxiety symptoms based on up to N=4161 participants (2363 female) aged 24 years from the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort. Exposures Blood-based immunological and metabolic biomarkers (n=93) comprising inflammatory proteins, cell count, lipids, hormones, and metabolites. Main Outcomes and Measures ICD-10 diagnosis of depression, 11 individual depressive and anxiety symptoms, and four domain scores were used as outcomes. Confounders included sex assigned at birth, body mass index, smoking, and alcohol use. Results After adjusting for potential confounders and multiple testing, depression was associated with changes in concentrations of specific immuno-metabolic markers (IL-6, CDCP1, neutrophil count, and insulin), and greater number of extreme-valued inflammatory markers. We identified three distinct affective symptom-related biomarker clusters, including one comprising inflammatory cytokines, chemokines and cells which was positively associated with somatic and mood symptoms, and one comprising liver-related biomarkers which was negatively associated with anxiety symptoms. Then using Partial Least Squares regression we identified two latent variables that capture the biomarker-symptom associations (Component 1: Somatic-Depressive-Inflammation and Component 2: Anxiety-Hepatic). Higher Component 1 score was associated with higher depressive symptom severity consistently over subsequent five years. Immuno-metabolic biomarkers performed poorly in predicting ICD-10 depression (0.569 Balanced Accuracy). However, within depression cases the addition of immuno-metabolic biomarkers improved the prediction of depression with high levels of mood (0.720 Balanced Accuracy) or anxiety symptoms (0.636 Balanced Accuracy). Conclusion and Relevance Depression is associated with disruption in immuno-metabolic homeostasis. Specific patterns of immuno-metabolic biomarkers are associated with differing subsets of affective symptoms, which are potentially relevant for poor depression prognosis. Immuno-metabolic biomarkers improve predictions of high levels of mood symptoms within people with depression, highlighting the symptom-level heterogeneity of depression and opportunities for immuno-metabolic biomarker-based subtyping, prediction, and targeted intervention.

Identification of 17 novel epigenetic biomarkers associated with anxiety disorders using differential methylation analysis followed by machine learning-based validation

Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs

Identifying clinical and proteomic markers for early diagnosis and prognosis prediction of major psychiatric disorders

Nominating novel proteins for anxiety via integrating human brain proteomes and genome-wide association study

Decoding depression: a comprehensive multi-cohort exploration of blood DNA methylation using machine learning and deep learning approaches

Digital phenotyping data and anomaly detection methods to assess changes in mood and anxiety symptoms across a transdiagnostic clinical sample

Cell-Type Specific Methylome-Wide Association Study of Anxiety Disorders

Serum metabolomics study of anxiety disorder patients based on LC-MS

Integrated genome-wide methylation and expression analyses provide predictors of diagnosis and early response to antidepressant in panic disorder

DNA Methylation Patterns in Relation to Acute Severity and Duration of Anxiety and Depression

Convergent functional genomics of anxiety disorders: translational identification of genes, biomarkers, pathways and mechanisms

DNA Methylation Signatures of Depressive Symptoms in Middle-aged and Elderly Persons: Meta-analysis of Multiethnic Epigenome-wide Studies

Exploring the use of immunomethylomics in the characterization of depressed patients: A proof-of-concept study

DNA methylation signature aberration as potential biomarkers in treatment-resistant schizophrenia: Constructing a methylation risk score using a machine learning method

Blood Immuno-metabolic Biomarker Signatures of Depression and Affective Symptoms in Young Adults

Epigenome-wide DNA methylation analysis of whole blood cells derived from patients with GAD and OCD in the Chinese Han population

Large-scale analysis of DNA methylation identifies cellular alterations in blood from psychosis patients and molecular biomarkers of treatment-resistant schizophrenia

Integrated Analysis of Methylomic and Transcriptomic Data to Identify Potential Diagnostic Biomarkers for Major Depressive Disorder

Epigenome-Wide DNA Methylation in Unipolar Depression: Predictive Biomarker of Antidepressant Treatment Response?

DNA methylation differences in stress-related genes, functional connectivity and gray matter volume in depressed and healthy adolescents

Neuroimaging and epigenetic analysis reveal novel epigenetic loci in major depressive disorder